Clinical Trial VICCPHI1359


A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Principal Investigator(s)

Emily Chan


  • Protocol No. VICCPHI1359
  • Open Date: 12/03/2013
  • Staging: Phase I/II
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the objective response rate (ORR) of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic tumors.
  • Disease Sites: Breast; Pancreatic; Lung; Gastric/Gastroesophageal
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Ipilimumab; Nivolumab (BMS-936558)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01928394
  • Secondary Protocol No: CA209032



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.